1 day Ago By Defense World Staff
Enfusion, Inc. ( NYSE:ENFN – Get Free Report ) was the recipient of a large drop in short interest in August. As of August 31st, there was short interest totalling 1,900,000 shares, a drop of 17.
7% from the August 15th total of 2,310,000 shares. Approximately 3.9% of the shares of the stock are short sold.
Based on an average daily volume of 374,600 shares, the short-interest ratio is currently 5.1 days. Insider Activity at Enfusion In related news, insider Bronwen Bastone sold 18,241 shares of Enfusion stock in a transaction dated Thursday, June 20th.
The stock was sold at an average price of $8.11, for a total value of $147,934.51.
Following the completion of the transaction, the insider now directly owns 198,913 shares of the company’s stock, valued at $1,613,184.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link .
Insiders own 36.44% of the company’s stock. Institutional Inflows and Outflows Large investors have recently made changes to their positions in the stock.
Brown Capital Management LLC boosted its stake in Enfusion by 6.5% during the 4th quarter. Brown Capital Management LLC now owns 11,817,661 shares of the company’s stock worth $114,631,000 after acquiring an additional 724,502 shares during the last quarter.
Scalar Gauge Management LLC bought a new position in shares of Enfusion during the fourth quarter worth $1,993,000. Wasatch Advisors LP grew its holdings in shares of Enfusion by 34.2% in the 1st quarter.
Wasatch Advisors LP now owns 792,083 shares of the company’s stock valued at $7,327,000 after buying an additional 201,771 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Enfusion by 57.5% in the 2nd quarter.
Dimensional Fund Advisors LP now owns 524,142 shares of the company’s stock valued at $4,466,000 after buying an additional 191,436 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in Enfusion during the 2nd quarter worth $683,000. Institutional investors and hedge funds own 81.
05% of the company’s stock. Enfusion Stock Up 3.9 % Enfusion ( NYSE:ENFN – Get Free Report ) last issued its quarterly earnings results on Tuesday, August 6th.
The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.
01). Enfusion had a return on equity of 6.17% and a net margin of 1.
98%. The business had revenue of $49.46 million for the quarter, compared to analyst estimates of $50.
27 million. Sell-side analysts predict that Enfusion will post 0.07 earnings per share for the current fiscal year.
Enfusion Company Profile ( Get Free Report ) Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. See Also Five stocks we like better than Enfusion Canadian Penny Stocks: Can They Make You Rich? Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion? Options Trading – Understanding Strike Price Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge What is a Bond Market Holiday? How to Invest and Trade Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.
com's FREE daily email newsletter ..
